Stock AnalizBio-rad Laboratories, Inc. BIO
Biotechnology: Laboratory Analytical Instruments · IPO 1980 · data as of November 13, 2026
Bio-rad Laboratories, Inc. (BIO) is a industrial company listed in the US with a market value of about $9.9B. In the twelve months to September 30, 2026 it had revenue of $2.6B and net income of $1.0B, a net margin of 39.5%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 9.7, a price to free cash flow of 29.9, 5-year revenue growth of 0% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 62% below the current price.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B | $2.5B | $2.3B | $2.3B | $2.2B | $2.1B |
| Net income | $1.0B | $760M | -$1.8B | -$637M | -$3.6B | $4.3B | $3.8B | $1.8B | $366M | $122M | $26M |
| Free cash flow | $329M | $375M | $290M | $218M | $82M | $536M | $476M | $359M | $156M | -$7M | $75M |
| EPS (diluted) | $37.71 | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 |
| Net margin | 39.5% | 29.4% | -71.9% | -23.9% | -129.4% | 145.6% | 149.8% | 76.1% | 16.0% | 5.7% | 1.3% |
| ROIC | — | 0.4% | 2.7% | 2.5% | 3.4% | 2.8% | 3.2% | 3.0% | -1.7% | 2.8% | 1.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $356.67, 3% below the current price; targets range from $280.00 to $440.00; the consensus rating is “Hold”; expected EPS is $9.61 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Bio-rad Laboratories’s P/E ratio?
About 9.7, based on the last twelve months of diluted earnings per share (forward P/E about 34.5).
Is Bio-rad Laboratories stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 62% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bio-rad Laboratories pay a dividend?
Not currently.
Is Bio-rad Laboratories a good stock to buy?
We do not give buy or sell advice. Bio-rad Laboratories scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.